Clinical Trials Logo

Clinical Trial Summary

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the joint cartilage, which is involved in the immune system leading to proinflammatory cytokine and metalloproteinase release. Knee osteoarthritis is the most common form. The healing is very slow and the damage is not fully recovered, so the degeneration process continues and no treatment modalities completely remove this process. Various methods are used in the treatment of OA and total joint replacement is performed in the patients with OA recently.

Ten patients with Kellgren-Lawrence grade II-III knee OA who had been applied for knee pain and received conservative treatment for 6 months and had no benefit will be taken to study. Patients will be assessed 7 (V1-7) times during the study. Clinical, immunologic and radiological treatment effectiveness and clinical improvement will be evaluated at the beginning of the treatment and in all follow-up patients participating in the study.


Clinical Trial Description

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the articular cartilage, caused with the release of proinflammatory cytokines and metalloproteinases. Knee osteoarthritis is the most common form. OA accounts for about 2% of public health problems and leads to a reduction in production, resulting in indirect costs. Regardless of the etiology (age, trauma, overuse, autoimmune arthritis, infection, etc.), the recovery is very slow, the damage is not fully recovered, and the result is secondary fibrosis healing. Therefore, the degeneration process continues and no treatment modality does not completely eliminate this process. Various methods are used in the treatment of OA. The most commonly used of these methods are the physical and educational therapy offered by the American Society of Orthopedic Surgeons (AAOS), symptomatic treatment with acetaminophen and non-steroidal anti-inflammatory drugs, and steroid injection. In patients with end-stage OA who do not benefit from these treatment methods, total joint replacement is performed. Mesenchymal stem cells are multiple potent progenitor cells. In recent years, there have been promising developments in the treatment of patients who cannot be cured by stem cell therapy. Mesenchymal stem cells have been used in clinical and experimental animal studies due to their immunosuppressive effects, limited immunogenetic effects, their ability to be produced in culture and their multilevel structure. At the same time, studies have shown that mesenchymal stem cells have potential to differentiate into osteocytes, chondrocytes, muscle cells and nerve cells. Because of these features, mesenchymal stem cells have been used clinically for OA treatment. In addition, studies have shown that mesenchymal stem cells can be obtained from bone marrow, periosteum, trabecular bone, fat tissue, synovia, muscle tissue, milk tooth, umbilical cord and Wharton gel. Wharton gel is a mucous connective tissue in the umbilical cord and consists of myofibroblast-like stromal cells, collagen fibers, proteoglycans and hyaluronic acid. Because of these properties, it can be used as a source of stem cells.

dipocytokines are cytokines secreted from adipose tissue and act as intercellular signal proteins. These cytokines include adipose tissue and cells nutrient uptake, regulation of energy balance, insulin activation, lipid and glucose metabolism, angiogenesis, regulation of blood pressure, coagulation, immunostimulation, pro-inflammatory and anti-inflammatory effects.

Stem cell applications are now widely used in different tissues. In the recovery of chondral damage; Since cells have little capacity for regeneration and proliferation, stem cell derived differentiation is needed. In this study, it will be tried to show that chondral damage can be treated with wharton gel-derived stem cells. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04313894
Study type Interventional
Source TC Erciyes University
Contact Ali E Günay, MD
Phone +905556493401
Email alieraygunay@hotmail.com
Status Recruiting
Phase Phase 2
Start date January 1, 2019
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04460989 - Assessment of Patient Satisfaction After Arthroplasty: A Comparative Study by Implant Type
Recruiting NCT02411097 - Role of Femoral Nerve Block on Prevention of Postoperative Deep Venous Thromboembolism N/A
Not yet recruiting NCT05435690 - Evaluation of a New Navigation System in Computer-assisted Total Knee Arthroplasty N/A
Completed NCT06308887 - Comparison of Ultrasound-Guided Perimeniscal Steroid and 5% Dextrose Injections in Knee Osteoarthritis Phase 4
Recruiting NCT03951545 - Clinical and Radiological Impact of Tibial Cutting Int Total Knee Arthroplasty, Accelerated Navigation Versus Extramedullary Targeting N/A
Recruiting NCT06302075 - Functional Recovery After Medial Monocompartmental Knee Prosthesis: One Day Protocol Versus Fast Protocol N/A
Not yet recruiting NCT05877027 - Exercise vs. Topical Diclofenac vs. PRP N/A
Recruiting NCT04424628 - Radiotherapy 3 vs 6 Gy in Gonarthrosis and Coxarthrosis N/A
Completed NCT04577521 - The Safety and Efficacy of Single IA-HA Injection in Patients With Knee Osteoarthritis: A Prospective Study
Recruiting NCT05814471 - Validation orthèse Pour Gonarthrose N/A
Completed NCT01773226 - Evaluation of Intra-articular Injection of Autologous Protein Solution ("APS(TM)") for the Treatment of Osteoarthritis (OA) N/A
Completed NCT02638831 - Ketorol Gel in Gonarthrosis and Low Back Pain Phase 4
Not yet recruiting NCT06314191 - Adipose Tissue and Symptomatic Gonarthrosis N/A
Completed NCT02977936 - Management of Joint Pain Associated With Osteoarthritis of the Knee With Association of Plant Extracts.
Recruiting NCT05062109 - Multimodal Geriatric Pre-authorization Before Scheduled Orthopedic Surgery N/A
Recruiting NCT02251535 - In-vivo Comparison of Different Levels of Femoral Rollback in a Primary Total Knee Arthroplasty N/A
Active, not recruiting NCT03734315 - Routine Application of Ostenil® in Patients With Gonarthrosis
Completed NCT03389607 - The Role of SCUBE-1 in Ischemia-reperfusion Injury
Completed NCT04225182 - Evaluation of the Effectiveness of a Muscular Strengthening Protocol With an Instrumented Orthosis for Gonarthrosis Patients N/A
Recruiting NCT06087705 - Real-life Assessment of the Safety and Performance of the SYNOVIUM HCS Device